Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series.
Identifieur interne : 000D66 ( PubMed/Curation ); précédent : 000D65; suivant : 000D67Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series.
Auteurs : J Mikel Hubanks [États-Unis] ; Eric C. Umbreit ; R Jeffrey Karnes ; Robert P. MyersSource :
- European urology [ 1873-7560 ] ; 2012.
English descriptors
- KwdEn :
- Adult, Aged, Carbolines (therapeutic use), Coitus, Erectile Dysfunction (drug therapy), Erectile Dysfunction (prevention & control), Humans, Male, Middle Aged, Neoplasm Grading, Phosphodiesterase 5 Inhibitors (therapeutic use), Prospective Studies, Prostate (drug effects), Prostate (innervation), Prostate (surgery), Prostate-Specific Antigen (blood), Prostatectomy (methods), Prostatic Neoplasms (surgery), Quality of Life, Surveys and Questionnaires, Tadalafil, Treatment Outcome, Urinary Incontinence (prevention & control).
- MESH :
- chemical , blood : Prostate-Specific Antigen.
- chemical , therapeutic use : Carbolines, Phosphodiesterase 5 Inhibitors.
- drug effects : Prostate.
- drug therapy : Erectile Dysfunction.
- innervation : Prostate.
- methods : Prostatectomy.
- prevention & control : Erectile Dysfunction, Urinary Incontinence.
- surgery : Prostate, Prostatic Neoplasms.
- Adult, Aged, Coitus, Humans, Male, Middle Aged, Neoplasm Grading, Prospective Studies, Quality of Life, Surveys and Questionnaires, Tadalafil, Treatment Outcome.
Abstract
Patients with newly diagnosed localized prostate cancer who choose surgery want cure and decent quality of life, namely, pad-free urinary control and, often, erectile function satisfactory for sexual intercourse.
DOI: 10.1016/j.eururo.2011.11.046
PubMed: 22154730
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D66
Links to Exploration step
pubmed:22154730Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series.</title><author><name sortKey="Hubanks, J Mikel" sort="Hubanks, J Mikel" uniqKey="Hubanks J" first="J Mikel" last="Hubanks">J Mikel Hubanks</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Umbreit, Eric C" sort="Umbreit, Eric C" uniqKey="Umbreit E" first="Eric C" last="Umbreit">Eric C. Umbreit</name></author><author><name sortKey="Karnes, R Jeffrey" sort="Karnes, R Jeffrey" uniqKey="Karnes R" first="R Jeffrey" last="Karnes">R Jeffrey Karnes</name></author><author><name sortKey="Myers, Robert P" sort="Myers, Robert P" uniqKey="Myers R" first="Robert P" last="Myers">Robert P. Myers</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="doi">10.1016/j.eururo.2011.11.046</idno><idno type="RBID">pubmed:22154730</idno><idno type="pmid">22154730</idno><idno type="wicri:Area/PubMed/Corpus">000D66</idno><idno type="wicri:Area/PubMed/Curation">000D66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series.</title><author><name sortKey="Hubanks, J Mikel" sort="Hubanks, J Mikel" uniqKey="Hubanks J" first="J Mikel" last="Hubanks">J Mikel Hubanks</name><affiliation wicri:level="1"><nlm:affiliation>Department of Urology, Mayo Clinic, Rochester, MN, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, Mayo Clinic, Rochester, MN</wicri:regionArea></affiliation></author><author><name sortKey="Umbreit, Eric C" sort="Umbreit, Eric C" uniqKey="Umbreit E" first="Eric C" last="Umbreit">Eric C. Umbreit</name></author><author><name sortKey="Karnes, R Jeffrey" sort="Karnes, R Jeffrey" uniqKey="Karnes R" first="R Jeffrey" last="Karnes">R Jeffrey Karnes</name></author><author><name sortKey="Myers, Robert P" sort="Myers, Robert P" uniqKey="Myers R" first="Robert P" last="Myers">Robert P. Myers</name></author></analytic><series><title level="j">European urology</title><idno type="eISSN">1873-7560</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Carbolines (therapeutic use)</term><term>Coitus</term><term>Erectile Dysfunction (drug therapy)</term><term>Erectile Dysfunction (prevention & control)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Grading</term><term>Phosphodiesterase 5 Inhibitors (therapeutic use)</term><term>Prospective Studies</term><term>Prostate (drug effects)</term><term>Prostate (innervation)</term><term>Prostate (surgery)</term><term>Prostate-Specific Antigen (blood)</term><term>Prostatectomy (methods)</term><term>Prostatic Neoplasms (surgery)</term><term>Quality of Life</term><term>Surveys and Questionnaires</term><term>Tadalafil</term><term>Treatment Outcome</term><term>Urinary Incontinence (prevention & control)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Prostate-Specific Antigen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Carbolines</term><term>Phosphodiesterase 5 Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Prostate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Erectile Dysfunction</term></keywords><keywords scheme="MESH" qualifier="innervation" xml:lang="en"><term>Prostate</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Prostatectomy</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Erectile Dysfunction</term><term>Urinary Incontinence</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Prostate</term><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Coitus</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Grading</term><term>Prospective Studies</term><term>Quality of Life</term><term>Surveys and Questionnaires</term><term>Tadalafil</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with newly diagnosed localized prostate cancer who choose surgery want cure and decent quality of life, namely, pad-free urinary control and, often, erectile function satisfactory for sexual intercourse.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">22154730</PMID><DateCreated><Year>2012</Year><Month>04</Month><Day>03</Day></DateCreated><DateCompleted><Year>2012</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur. Urol.</ISOAbbreviation></Journal><ArticleTitle>Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series.</ArticleTitle><Pagination><MedlinePgn>878-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2011.11.046</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Patients with newly diagnosed localized prostate cancer who choose surgery want cure and decent quality of life, namely, pad-free urinary control and, often, erectile function satisfactory for sexual intercourse.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Determine in a prospective study the positive surgical margin rate and functional outcomes for a consecutive series of patients undergoing open radical retropubic prostatectomy (ORRP) with bilateral neurovascular bundle preservation (BNVBP) performed by one experienced surgeon.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Of 197 consecutive patients undergoing BNVBP during 2008, 123 were evaluable, allowing both immediate postoperative phosphodiesterase type 5 inhibition (PDE5i) and a third-party questionnaire with validated urinary and erectile function domains provided preoperatively and at 3, 6, and 12 mo postoperatively.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Two interventions were used: (1) ORRP with ×4.3 optical loupes and constant digital tactile monitoring during BNVBP preceded by high anterior release (HAR) of levator fascia and neurovascular bundles and (2) early postoperative PDE5i.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Age; biopsy Gleason score; clinical stage; preoperative prostate-specific antigen level; pathologic grade; stage; margin status; University of California, Los Angeles Prostate Cancer Index domain for urinary pad use and bother; and International Index of Erectile Function-5 (IIEF-5) were used.</AbstractText><AbstractText Label="RESULTS AND LIMITATIONS" NlmCategory="CONCLUSIONS">Surgical margins were positive in 1 of the 123 evaluable patients (1%). At 1 yr, 95% of patients were pad-free. Satisfactory erectile function was achieved by 109 patients (89%): 82 (67%) scored an IIEF-5 of 22-25, and 27 (22%) scored <22-25 with ≥4 on either satisfaction or confidence questions or achieved "full" erection within the first year. Mean hospital stay was 1.3 d. Limitations were (1) observational, noncomparative, single-surgeon series and (2) in third-party methodology, failure to capture patient answers for all questionnaire intervals with resultant inability to address durability of functional results for all patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ORRP using ×4.3 optical loupe magnification, constant haptic feedback in BNVBP with HAR, and immediate postoperative PDE5i yielded satisfactory outcomes.</AbstractText><CopyrightInformation>Copyright © 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hubanks</LastName><ForeName>J Mikel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Urology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umbreit</LastName><ForeName>Eric C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Karnes</LastName><ForeName>R Jeffrey</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Robert P</ForeName><Initials>RP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002243">Carbolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058986">Phosphodiesterase 5 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>742SXX0ICT</RegistryNumber><NameOfSubstance UI="D000068581">Tadalafil</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur Urol. 2012 May;61(5):885-6; discussion 886-7</RefSource><PMID Version="1">22230712</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002243">Carbolines</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003075">Coitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007172">Erectile Dysfunction</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000517">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060787">Neoplasm Grading</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D058986">Phosphodiesterase 5 Inhibitors</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011467">Prostate</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000294">innervation</QualifierName><QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017430">Prostate-Specific Antigen</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011468">Prostatectomy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000601">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011788">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011795">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000068581">Tadalafil</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014549">Urinary Incontinence</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000517">prevention & control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S0302-2838(11)01340-6</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2011.11.046</ArticleId><ArticleId IdType="pubmed">22154730</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/HapticV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000D66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Ticri/CIDE
|area= HapticV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:22154730
|texte= Open radical retropubic prostatectomy using high anterior release of the levator fascia and constant haptic feedback in bilateral neurovascular bundle preservation plus early postoperative phosphodiesterase type 5 inhibition: a contemporary series.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22154730" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a HapticV1
| This area was generated with Dilib version V0.6.23. |  |